3 recruiting, 1 completed, 1 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow CDX-1140: new trials by email Literature Review of CDX-1140 trials Research Report on CDX-1140
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-08 | 2026-10-30 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients CDX-301, CDX-1140, Research blood draw - Pancreatic Cancer, Cancer of the Pancreas | Phase 2 | Terminated | Washington University School of Medicine | 16 | 2021-08-13 | 2024-10-08 |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) 6MHP, NeoAg-mBRAF, PolyICLC - Melanoma, Ocular Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 22 | 2020-09-28 | 2024-07-16 |
Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Fallopian Tube Neoplasms (1) · Laryngeal Neoplasms (1) · Melanoma (1) · Mouth Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Nevus (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uveal Melanoma (1)
National Cancer Institute (NCI) (2) · Craig L Slingluff, Jr (1) · Roswell Park Cancer Institute (1) · Washington University School of Medicine (1)
United States (5)
Craig L. Slingluff, Jr., MD (1) · Emese Zsiros (1) · Matin Imanguli (1) · Roheena Z Panni, M.D. (1) · Tim F Greten, M.D. (1)
R01CA262506 (1), UM1CA186691 (1)